JinMatrix Receives MFDS Manufacturing Approval for New HPV Diagnostic Kit Product
[Asia Economy Reporter Lee Gwan-joo] JinMatrix announced on the 11th that it has obtained manufacturing approval from the Ministry of Food and Drug Safety for its new human papillomavirus (HPV) diagnostic product, 'NeoPlex HPV29 Detection.'
JinMatrix's new NeoPlex product is based on the proprietary 'C-Tag' technology and enables simultaneous multiplex diagnosis of 29 types of human papillomavirus, the causative virus of cervical cancer, in a single test. Its excellent sensitivity and specificity have been proven through large-scale clinical trials.
Compared to existing products, the analysis time has been reduced by more than one hour, allowing results to be obtained within two hours. It accurately identifies viral genotypes according to the risk level of cervical cancer, achieving high test accuracy.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
A JinMatrix official stated, “The adoption of HPV DNA testing in the field of cervical cancer diagnosis is becoming a global standard of care. Based on the advantages of the NeoPlex product, which is easy, fast, and accurate, we will expand our market share in the domestic and international molecular diagnostics markets amid the growing market.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
